WO2003033471A1 - Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant - Google Patents

Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant Download PDF

Info

Publication number
WO2003033471A1
WO2003033471A1 PCT/JP2001/009121 JP0109121W WO03033471A1 WO 2003033471 A1 WO2003033471 A1 WO 2003033471A1 JP 0109121 W JP0109121 W JP 0109121W WO 03033471 A1 WO03033471 A1 WO 03033471A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridone
nitro
ethylcarbamoyl
pharmaceutical composition
nitrooxy
Prior art date
Application number
PCT/JP2001/009121
Other languages
English (en)
Japanese (ja)
Inventor
Yasumi Uchida
Masashi Ogawa
Norihiro Iibuchi
Tadashi Morita
Original Assignee
Tobishi Pharmaceutical Co.,Ltd
Cardiovascular Institute,Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobishi Pharmaceutical Co.,Ltd, Cardiovascular Institute,Ltd filed Critical Tobishi Pharmaceutical Co.,Ltd
Priority to PCT/JP2001/009121 priority Critical patent/WO2003033471A1/fr
Publication of WO2003033471A1 publication Critical patent/WO2003033471A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention se rapporte à un composé représenté par le formule (I) ou à un sel de ce dernier. Ce composé permet d'ouvrir les canaux potassium sensibles au calcium et est utile dans le traitement des maladies cardiaques ischémiques, de l'hypertension, etc. (Dans la formule (I), R1 est hydrogène, alkyle inférieur, aminoalkyle inférieur substitué par un ou deux alkyles inférieurs, ou benzyle qui n'a pas été substitué ou a été substitué indifféremment par un à trois substituants choisis parmi alkoxys inférieurs, halogènes, cyano, trifluorométhyle, méthylènedioxy, et cyclopropylméthyloxy ; R2 est hydrogène ou un groupe nitrooxyalkyle inférieur ; et R3 est hydrogène ou un groupe nitrooxyalkyle inférieur. )
PCT/JP2001/009121 2001-10-17 2001-10-17 Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant WO2003033471A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/009121 WO2003033471A1 (fr) 2001-10-17 2001-10-17 Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/009121 WO2003033471A1 (fr) 2001-10-17 2001-10-17 Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant

Publications (1)

Publication Number Publication Date
WO2003033471A1 true WO2003033471A1 (fr) 2003-04-24

Family

ID=11737840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/009121 WO2003033471A1 (fr) 2001-10-17 2001-10-17 Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant

Country Status (1)

Country Link
WO (1) WO2003033471A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015608A1 (fr) * 1991-02-27 1992-09-17 Lacer S.A. AGENTS ANTI-HYPERTENSIFS A BASE DE DIPEPTIDES N-($G(a)-SUBSTITUE-PYRIDINYLE)CARBONYLE
US5716971A (en) * 1993-04-28 1998-02-10 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
EP0882716A1 (fr) * 1996-11-19 1998-12-09 Nisshin Flour Milling Co., Ltd. Derives de pyridinecarboxamide
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015608A1 (fr) * 1991-02-27 1992-09-17 Lacer S.A. AGENTS ANTI-HYPERTENSIFS A BASE DE DIPEPTIDES N-($G(a)-SUBSTITUE-PYRIDINYLE)CARBONYLE
US5716971A (en) * 1993-04-28 1998-02-10 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
EP0882716A1 (fr) * 1996-11-19 1998-12-09 Nisshin Flour Milling Co., Ltd. Derives de pyridinecarboxamide
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANTICK J.R. ET AL.: "New non-peptide angiotensin II receptor antagonists. 1: Structure-activity relationships of a series of 2(1H)-pyridinones", BIOORG. MED. CHEM. LETT., vol. 4, no. 1, 1994, pages 121 - 126, XP002907771 *

Similar Documents

Publication Publication Date Title
US7414071B2 (en) Methods of treatment with selective EP4 receptor agonists
EP2125695B1 (fr) Composes donneurs d'oxyde nitrique
JP2007500684A (ja) 心臓血管疾患治療用のアンギオテンシン−ｉｉ受容体遮断薬としてのロサルタン、バルサルタン、カンデサルタン、テルミサルタン、エプロサルタンおよびオルメサルタンのニトロオキシ誘導体
EP3348548A1 (fr) Molécule de promédicament libérant de l'oxyde nitrique
JP2005526696A5 (fr)
EP0539509A1 (fr) Derives de 4-alkylimidazole.
SK12462001A3 (sk) Inhibítory metaloproteáz
SU1470190A3 (ru) Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила
EP0950418A2 (fr) Composition pour la prévention et le traitement de maladies ischémiques
SU1635899A3 (ru) Способ получени 3-[(1Н-имидазол-4-ил)метил]-2-оксибензолметанолов
CN105153141A (zh) 苯并咪唑衍生物及其制备方法和医药用途
IE921771A1 (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for¹their preparation and their use in medicaments
JP3093419B2 (ja) １，４‐ベンゾチアゼピン誘導体
JPH07267954A (ja) 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１ノナン−化合物、その製法及び抗不整脈剤
JP3712529B2 (ja) ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩
EP0718289B1 (fr) Nouveaux dérivés d'acide parabanique comme inhibiteurs d'aldose réductase
WO2003033471A1 (fr) Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant
CN112390782B (zh) 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途
JPH0971534A (ja) 医薬組成物
EP0718290A1 (fr) Dérivés carboxyalcoyle hétérocycliques
CA2147762A1 (fr) Agent soulageant les troubles circulatoires
JP3748935B2 (ja) オキシインドール誘導体
WO1994014769A1 (fr) Derive indolique a substitution n
JPS6348273A (ja) キノロン強心剤
CN101691351B (zh) 4-胺基丙烯基苯基-1,4-二氢吡啶类的合成及其药物用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP